54 - Pharmacotherapy of schizophrenia and psychotic disorders (Ott) Flashcards

1
Q

Key features that define psychotic disorders

  • ___ - fixed false beliefs that are not amenable to change even with conflicting evidence
  • ___ - perception-like experiences that occur without an external stimulus (usually ___ , but can be visual, tactile, or olfactory)
  • disorganized thinking and speech
  • disorganized or abnormal motor behavior
  • negative symptoms
A
  • delusions
  • hallucinations, auditory
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Disease Course in Schizophrenia

onset late adolescence to early adulthood

men - late ___, early ___

women - late ___ , early ___

A

teens, 20s
20s, 30s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Link to Substance Use

  • more than 75% of people with schizophrenia use tobacco

smoking is associated with induction of CYP ___ due to hydrocarbons inhaled.
- decreases serum concentrations of ___ substrate antipsychotics (olanzapine, asenapine, clozapine, loxapine)

A

1A2
1A2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Link to Substance Use

  • longer illness goes untreated, more likely it is that the patient will missuse a substance
  • marijuana, cocaine, and amphetamine use can hasten ___ of schizoprenia, reduce time to ___, and exacerbate symtoms
  • substance use treatment and mental health treatment should be undertaken at the same time
A

onset, relapse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

T or F: all antipsychotics are considered to be equally effective in clinical trials and in generally equivalent doses in a large population . (Except clozapine - most effective)

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

antipsychotic drug selection

1st line) ___ antipsychotic drug therapy
- unless patient presents with reasons to consider IM depot drug therapy first

A

oral

changing injection perception to convienence and not punishment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

typical antipsychotics

older agents - primarily ___ receptor antagonists

efficacy for positive symptoms similar to ___ antipsychotics (except ___)

examples: (6)

A

D2
atypical, clozapine
- haloperidol
- chlorpromazine
- fluphenazine
- perphenazine
- loxapine
- thioridazine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

typical antipsychotics clinical pearls

  • ___ - most commonly used (routine and prn)
  • ___ is rarely used due to a black box warning for QTc prolongation
  • more ___ with higher potency typicals - and atypical antipsychotics risperidone and paliperidone
  • are very effective for treating ___ symptoms, but are likely to worsen ___ and cognitive symptoms
A
  • haloperidol
  • thioridazine
  • EPS
  • positive, negative
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

atypical antipsychotics

  • ___ and ___ antagonism
  • less ___ than typicals; more ___ side effects
    (13)
A
  • D2, 5HT2A
  • EPS, metabolic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

partial agonists

  • stabilized ___ transmission - not too much, not too little
  • associated with more ___ than other antipsychotics
  • approved for adjunct treatment in depression so all have boxed warnign for ___ thoughts/behavior
A
  • dopamine
  • akathisia
  • suicidal
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

partial agonists

aripiprazole
- D2 partial agonist and 5HT2A antagonist
- ___ and ___ substrate
- moderate ___
- ___ weight gain

A
  • 2D6, 3A4
  • akathisia
  • low
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

partial agonists

brexpiprazole
- D2 partial agonist and 5HT2A antagonist
- ___ and ___ substrate
- moderate ___
- ___ weight gain

A
  • 2D6, 3A4
  • akathisia
  • low-moderate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

partial agonist

cariprazine
- ___ / ___ partial agonist and 5HT2A antagonist
- ___ substrate
- moderate ___
- ___ weight gain

A
  • D2/D3
  • 3A4
  • akathisia
  • low-moderate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

the “pines”

  • less ___ antagonism, more ___ antagonism
  • significantly less ___
  • ___ weight gain than other agents
A
  • D2, 5HT2A
  • EPS
  • higher
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

the “pines”

asenapine
- ___ and ___ formulations
- metalic taste
- ___ substrate
- ___ prolongation

A
  • sublingual, patch
  • 1A2
  • QTc
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

the “pines”

clozapine
- most effective
- ___ substrate

boxed warnings
- ___ , orthostasis, bradycardia, syncope, ___ , myocarditis, cardiomypathy

SE
- ___ , weight ___ , constipation, hypersalivation, dry mouth, GI ___ with obstruction risk, ___ prolongation

A
  • 1A2
  • neutropenia, seizures
  • sedation, gain, hypomotility, QTc
17
Q

the “pines”

olanzapine
- may be more effective
- ___ substrate
- significant weight ___ and ___
- high risk ___ syndrome
- ___ warning
- anticholinergic

A
  • 1A2
  • gain, sedation
  • metabolic
  • DRESS
18
Q

the “pines”

quetiapine
- dibenzodiazepine - some misuse potential
- ___ substrate
- ___ prolongations, weight ___ , and ___
- boxed warning for ___ ideation

A
  • 3A4
  • QTc, gain, sedation
  • suicidal
19
Q

asenapine transdermal patch (Secuado)

  • apply one patch every ___ hours
  • rotate sites
  • warnings for ___ prolongation, increased effectiveness of antihypertensives (orthostatic hypotension SE)
  • ___ and ___ substate - reduce dose of patch if give with strong ___ inhibitors like ___
A
  • 24
  • QTc
  • UGT, 1A2, 1A2, fluvoxamine
20
Q

Clozapine REMS

  • pharmacy cannot dispense without an absolute neutrophil count (ANC) lab report within the past 7 days
  • online system streamlines reporting and reduces ANC to 1500/µL to intiate therapy
  • monitoring timelines weekly for ___ months, biweekly x ___ months, then every ___ weeks
A

6, 6, 4

21
Q

Olanzapine/Samidorphan (Lybalvi)

  • samidorphan added to mitigate weight ___ and ___ syndrome
  • samidorphan is an ___ antagonist with preferential activity at the mu receptor
  • CI in patients currently taking opioids or in withdrawal
A
  • gain, metabolic
  • opioid
22
Q

the “dones”

  • ___ and ___ antagonists
  • variable EPS and metabolic SE
A

D2, 5HT2A

23
Q

the “dones”

iloperidone
- high risk for ___ and ___
- ___ prologation
- ___ substrate

A
  • orthostasis, syncope
  • QTc
  • 2D6
24
Q

the “dones”

lurasidone
- ___ substrate
- higher risk for ___
- warning for ___ thoughts - adjunct for bipolar depression
- take with ____ (350 calories) to increase bioavailability

A
  • 3A4
  • akathisia
  • suicidal
  • food
25
Q

the “dones”

ziprasidone
- ___ prolongation (CI)
- ___ warning
- take with ___ to increase absorption and bioavailability
- ___ substrate (1/3) and aldehyde oxidase (2/3) (less worry for CYP interactions)

A
  • QTc
  • DRESS
  • food
  • 3A4
26
Q

more “dones”

  • highest ___ blockade for atypical antipsychotics
  • high risk ___ , moderate risk metabolite side effects
A

D2
EPS

27
Q

more “dones”

risperidone
- ___ substrate (minor ___ substrate)
- ___ , ___ , weight ___, sedation, ___

A
  • 2D6, 3A4
  • EPS, hyperprolactinemia, gain, orthostasis
28
Q

more “dones”

paliperidone
- ___ eliminated - dose adjustments if impairment
- similar SE to ___
- ___ prolongation

A
  • renally
  • risperidone
  • QTc
29
Q

Lumateperone (Caplyta)

  • primarily ___ antagonism with postsynaptic D2 blockade and presynaptic ___ partial agonist
  • ___ risk for weight gain or metabolic side effects
  • ___ risk for EPS or akathisia
  • ___ substrate
A
  • 5HT2A, D2
  • low
  • low
  • 3A4
30
Q

pimavanserin (Nuplazid)

  • antipsychotic medication that is FDA-approved for the treatment of hallucinations or delusions in a patient with ___
  • MOA: ___ agonist and antagonists at the serotonin (5HT2A and 2C)
  • ___ substrate; dose adjustment needed if given with strong 3A4 inhibitors
  • some preliminary studies in schizophrenia
  • SE: peripheral edema, confusional states, nausea
A
  • Parkinson’s
  • inverse
  • 3A4
31
Q
A